Evaluation of Early Dementia (Mild Cognitive Impairment)

R S Osorio; V Berti; L Mosconi; Y Li; L Glodzik; S De Santi; M J de Leon

doi:10.1016/j.cpet.2009.12.003

Evaluation of Early Dementia (Mild Cognitive Impairment)

PET Clin. 2010 Jan;5(1):15-31. doi: 10.1016/j.cpet.2009.12.003. Epub 2010 May 27.

Authors

R S Osorio¹, V Berti², L Mosconi³, Y Li³, L Glodzik³, S De Santi³, M J de Leon⁴

Affiliations

¹ Department of Psychiatry, Center for Brain Health, Silberstein Alzheimer's Institute, Center of Excellence on Brain Aging, NYU Langone Medical Center, 145 East 32nd Street, 5th Floor, New York, NY 10016, USA; Department of Pathology and Psychiatry, Alzheimer's Disease Center, Silberstein Alzheimer's Institute, Center of Excellence on Brain Aging, NYU Langone Medical Center, 145 East 32nd Street, 2nd Floor, New York, NY 10016, USA; Alzheimer's Disease Research Unit, CIEN Foundation-Reina Sofia Foundation, Carlos III Institute of Health, Valderrebollo 5, (Complejo Alzheimer), PAU de Vallecas, Madrid 28031, Spain.
² Department of Psychiatry, Center for Brain Health, Silberstein Alzheimer's Institute, Center of Excellence on Brain Aging, NYU Langone Medical Center, 145 East 32nd Street, 5th Floor, New York, NY 10016, USA; Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Viale Morgagni 85, Florence 50134, Italy.
³ Department of Psychiatry, Center for Brain Health, Silberstein Alzheimer's Institute, Center of Excellence on Brain Aging, NYU Langone Medical Center, 145 East 32nd Street, 5th Floor, New York, NY 10016, USA.
⁴ Department of Psychiatry, Center for Brain Health, Silberstein Alzheimer's Institute, Center of Excellence on Brain Aging, NYU Langone Medical Center, 145 East 32nd Street, 5th Floor, New York, NY 10016, USA; Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. Electronic address: [email protected].

PMID: 27157481
DOI: 10.1016/j.cpet.2009.12.003

Abstract

Early diagnosis of Alzheimer disease (AD) is one of the major challenges for the prevention of this dementia. The pathologic lesions associated with AD develop many years before the clinical manifestations of the disease become evident, during a likely transitional period between normal aging and the appearance of first cognitive symptoms. AD biomarkers are needed not only to reveal these early pathologic changes but also to monitor progression in cognitive and behavioral decline and brain lesions. PET neuroimaging can reliably assess indirect and direct aspects of the molecular biology and neuropathology of AD. This article reviews the use of [18F] 2-fluoro-2-deoxy-D-glucose-PET and amyloid PET imaging in the early detection of AD.

Keywords: Dementia; Early diagnosis; Mild cognitive impairment; PET scan.

Publication types

Review